Healthcare Intelligence
Oncology
Real-time intelligence, expert analysis, and verified research for the Oncology industry. Stay ahead in 3 minutes a day.
Stay ahead of Oncology in 3 minutes a day.
Expert-verified intelligence delivered to your inbox every morning.
Free forever. No spam. Unsubscribe anytime.
Pfizer's First Seagen ADC Fails Phase 3 Lung Cancer Trial
Sigvotatug vedotin missed primary endpoint in NSCLC study, but Pfizer remains confident in ongoing first-line trials.
Read full articleEU Approves Keytruda + Padcev for Cisplatin-Ineligible Bladder Cancer
First PD-1/ADC combo approved in EU for resectable MIBC, reducing death risk by 50% vs surgery alone.
Read full articleFDA Approves Trodelvy + Keytruda for First-Line Triple-Negative Breast Cancer
Gilead's ADC gets dual approvals as monotherapy and in combo with Merck's Keytruda for frontline mTNBC treatment.
Read full articleWorld's First CAR-T for Solid Tumors Approved in China
CARsgen's satri-cel breaks new ground as first CAR-T therapy approved for solid tumors in gastric cancer patients.
Read full articleEU Approves Trodelvy for First-Line Metastatic TNBC
First ADC approved in EU for frontline mTNBC in 20 years, showing 38% reduced risk of progression vs chemotherapy.
Read full articlePfizer's First Seagen ADC Fails Phase 3 Lung Cancer Trial
Sigvotatug vedotin missed primary endpoint in NSCLC study, but Pfizer remains confident in ongoing first-line trials.
Read full articleEU Approves Keytruda + Padcev for Cisplatin-Ineligible Bladder Cancer
First PD-1/ADC combo approved in EU for resectable MIBC, reducing death risk by 50% vs surgery alone.
Read full articleFDA Approves Trodelvy + Keytruda for First-Line Triple-Negative Breast Cancer
Gilead's ADC gets dual approvals as monotherapy and in combo with Merck's Keytruda for frontline mTNBC treatment.
Read full articleWorld's First CAR-T for Solid Tumors Approved in China
CARsgen's satri-cel breaks new ground as first CAR-T therapy approved for solid tumors in gastric cancer patients.
Read full articleEU Approves Trodelvy for First-Line Metastatic TNBC
First ADC approved in EU for frontline mTNBC in 20 years, showing 38% reduced risk of progression vs chemotherapy.
Read full articleStay ahead of Oncology in 3 minutes a day.
Live opportunity intelligence for your market, delivered to your inbox every morning. Read it over coffee.
Free forever. No spam. Unsubscribe anytime.